TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30953560

Group type: COMPARATOR
Intervention: Methylated INS cfDNA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unmethylated INS cfDNA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Methylated and unmethylated INS cfDNA pooled
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clinical measurements of β-cell function and pre-diabetes
Number of subjects: 40
Study: 30954166

Group type: EXPERIMENTAL
Intervention: Bacterial lyophilizates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-immunoglobulin E
Number of subjects: 0
Study: 30954352

Group type: EXPERIMENTAL
Intervention: HIPEC with mitomycinC/doxorubicin for 90 min
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: HIPEC with cisplatin for 90 min
Number of subjects: 140

Group type: COMPARATOR
Intervention: HIPEC with oxaliplatin for 30 min
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: HIPEC with 90 min (mitomycinC/doxorubicin or cisplatin)
Number of subjects: 140
Study: 30954510

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 350

Group type: COMPARATOR
Intervention: Dapagliflozin
Number of subjects: 350
Study: 30954640

Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 0
Study: 30954643

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study: 30954717

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (chemotherapy with ifosfamide/doxorubicin)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Surgery ± radiotherapy for low-risk patients
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intermediate-/high-risk therapy (chemotherapy ± surgery ± radiotherapy)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Predictors of event-free survival
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: High-risk patients
Number of subjects: 63
Study: 30955188

Group type: EXPERIMENTAL
Intervention: Evocalcet 1-8 mg orally once daily for 32 weeks
Number of subjects: 39
Study: 30955357

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 16443

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 16443
Study: 30955420

Group type: EXPERIMENTAL
Intervention: 20 mg/kg cannabidiol
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 10 mg/kg cannabidiol
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 30955983

Group type: EXPERIMENTAL
Intervention: Vegetarian diet (lacto-ovo vegetarians and vegans)
Number of subjects: 13935

Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 13935

Group type: COMPARATOR
Intervention: Nonvegetarian diet
Number of subjects: 13935
Study: 30956579

Group type: EXPERIMENTAL
Intervention: ISO-Gard
Number of subjects: 0
Study: 30956800

Group type: EXPERIMENTAL
Intervention: Mobile phone application for daily breathlessness rating (0-10 NRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily and weekly recall of breathlessness
Number of subjects: 0
Study: 30956961

Group type: EXPERIMENTAL
Intervention: Gum arabic (GA) 30 g/day for 12 weeks
Number of subjects: 47
Study: 30957229

Group type: EXPERIMENTAL
Intervention: Reinduction chemotherapy plus bortezomib
Number of subjects: 135
Study: 30957420

Group type: EXPERIMENTAL
Intervention: Comprehensive safer conception package including ART for HIV-positive partners, PrEP for HIV-negative partners, SMS surveys for tracking, counselling on self-insemination, referrals for circumcision and fertility care.
Number of subjects: 74
Study: 30957581

Group type: EXPERIMENTAL
Intervention: PEGylated non-biologic drugs
Number of subjects: 0
Study: 30958020

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT) course (8-week guided)
Number of subjects: 8
Study: 30958033

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30958102

Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB) for fiducial marker placement
Number of subjects: 258
Study: 30958884

Group type: EXPERIMENTAL
Intervention: Higher BDI-II scores
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 2MST (2 min step test)
Number of subjects: 125
Study: 30958892

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg orally once daily (QD) 3 weeks on/1 week off combined with intravenous cetuximab 250 mg/m²
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various dose levels of regorafenib administered QD continuously or intermittently (3 weeks on/1 week off)
Number of subjects: 0
Study: 30959003

Group type: EXPERIMENTAL
Intervention: NPR with leakage
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NPR without leakage
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NPR with leakage in the posterior region
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NPR without leakage in the mid-periphery
Number of subjects: 40
Study: 30959163

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (9 doses, i.v., 1 dose every 21 days starting on day +14 post-AHCT)
Number of subjects: 32
Study: 30959477

Group type: EXPERIMENTAL
Intervention: Vitamin D (2800 IE daily)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 30961941

Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT)
Number of subjects: 3452

Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis
Number of subjects: 3452

Group type: EXPERIMENTAL
Intervention: CAT and mMRC classification
Number of subjects: 3452

Group type: EXPERIMENTAL
Intervention: CAT >10
Number of subjects: 3452
Study: 30962120

Group type: EXPERIMENTAL
Intervention: Low-sugar diet (added sugars comprised 2.5% to 4.0% of daily calories)
Number of subjects: 42
Study: 30962222

Group type: EXPERIMENTAL
Intervention: SIRPαFc (TTI-621), a novel CD47 decoy receptor, administered in clinical trial settings.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD47 expression on Sézary cells influenced by interleukin 4 (IL-4), IL-7, and IL-13.
Number of subjects: 0
Study: 30962233

Group type: EXPERIMENTAL
Intervention: Current treatment practices for PDN according to guidelines and local practices
Number of subjects: 1500
Study: 30962275

Group type: EXPERIMENTAL
Intervention: Higher cortical thickness in medial prefrontal, anterior cingulate, and orbitofrontal areas associated with YoE.
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Distinct gene expression profile in YoE-related brain regions.
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Genome-wide expression profile analysis of YoE-related brain regions.
Number of subjects: 122
Study: 30962330

Group type: EXPERIMENTAL
Intervention: Isavuconazole (single oral dose of isavuconazonium sulfate)
Number of subjects: 48
Study: 30962334

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (IMP-CS) at 15 mg/kg every 6 hours
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (IMP-CS) at 20 mg/kg every 6 hours
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (IMP-CS) at 25 mg/kg every 6 hours
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (IMP-CS)
Number of subjects: 56
Study: 30962681

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide/formoterol fumarate (AB/FF) 400/12 µg
Number of subjects: 1594

Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 µg
Number of subjects: 1594

Group type: COMPARATOR
Intervention: Aclidinium (AB) 400 µg
Number of subjects: 1594

Group type: COMPARATOR
Intervention: Formoterol (FF) 12 µg
Number of subjects: 1594
Study: 30962697

Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine U100 plus insulin aspart
Number of subjects: 0
Study: 30962703

Group type: EXPERIMENTAL
Intervention: Random forest method
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Generalized linear model
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Support vector machine
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Decision tree
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Feed-forward neural network
Number of subjects: 573

Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 573

Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 573
Study: 30962707

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg/day to 600 mg/day, titrated over 1-4 weeks)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 30962729

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg once daily)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 30962963

Group type: EXPERIMENTAL
Intervention: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion at 10 mg/m2/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion at 15 mg/m2/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion at 20 mg/m2/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion
Number of subjects: 9
Study: 30963179

Group type: EXPERIMENTAL
Intervention: Feminizing hormone therapy (FHT)
Number of subjects: 0
Study: 30963212

Group type: EXPERIMENTAL
Intervention: Neoadjuvant nab-PTX 260 mg/m2 with trastuzumab every 3 weeks for four cycles
Number of subjects: 18
Study: 30963506

Group type: EXPERIMENTAL
Intervention: Erenumab (140-mg subcutaneous dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norgestimate/ethinyl estradiol-containing oral contraceptive
Number of subjects: 0
Study: 30963691

Group type: EXPERIMENTAL
Intervention: Galunisertib (80 or 150 mg BID for 14 days per 28-day cycle)
Number of subjects: 149
Study: 30964425

Group type: EXPERIMENTAL
Intervention: Digital Mammography plus Tomosynthesis (DM plus DBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digital Mammography (DM)
Number of subjects: 0
Study: 30964436

Group type: EXPERIMENTAL
Intervention: e-message intervention (3 to 4 electronic weekly messages)
Number of subjects: 128
Study: 30964439

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention consisting of monthly telephone calls for 6 months by a case manager and weekly, one-way informational text messages.
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Completion of 4 or more phone calls during the intervention.
Number of subjects: 141
Study: 30964819

Group type: EXPERIMENTAL
Intervention: Anti-Saccharomyces cerevisiae mannan antibodies (ASCA)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Outer membrane porin C (OmpC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: CBir1
Number of subjects: 43

Group type: COMPARATOR
Intervention: Antineutrophil cytoplasmic antibodies
Number of subjects: 43
Study: 30965011

Group type: EXPERIMENTAL
Intervention: Double-Dose Alpha-1 Antitrypsin Augmentation Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30965288

Group type: EXPERIMENTAL
Intervention: Modern breath sampling system (Pneumopipe)
Number of subjects: 0
Study: 30967392

Group type: EXPERIMENTAL
Intervention: Idelalisib plus ofatumumab
Number of subjects: 27
Study: 30967435

Group type: EXPERIMENTAL
Intervention: Higher baseline serum uric acid (SUA)
Number of subjects: 539
Study: 30967831

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg/day for 5 consecutive days at baseline and 3 consecutive days 12 months later)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring strategies for alemtuzumab-treated patients
Number of subjects: 0
Study: 30968056

Group type: EXPERIMENTAL
Intervention: Full-dose aH5N1c vaccine (7.5 μg of hemagglutinin antigen per dose)
Number of subjects: 2372

Group type: COMPARATOR
Intervention: Half-dose aH5N1c vaccine
Number of subjects: 2372

Group type: EXPERIMENTAL
Intervention: Full-dose aH5N1c vaccine
Number of subjects: 2372
Study: 30968114

Group type: EXPERIMENTAL
Intervention: DASH diet (highest quartile)
Number of subjects: 50884

Group type: EXPERIMENTAL
Intervention: AHEI-2010 (highest quartile)
Number of subjects: 50884

Group type: EXPERIMENTAL
Intervention: AHEI-2010 (highest quartile, excluding alcohol)
Number of subjects: 50884

Group type: EXPERIMENTAL
Intervention: AMED (highest quartile)
Number of subjects: 50884
Study: 30968129

Group type: EXPERIMENTAL
Intervention: Maternal obesity (BMI ≥25 kg/m2)
Number of subjects: 35
Study: 30968137

Group type: EXPERIMENTAL
Intervention: Total protein intake (highest vs lowest quartile)
Number of subjects: 2641

Group type: EXPERIMENTAL
Intervention: Animal protein intake (highest vs lowest quartile)
Number of subjects: 2641

Group type: EXPERIMENTAL
Intervention: Animal-to-plant protein ratio (extreme quartile)
Number of subjects: 2641

Group type: EXPERIMENTAL
Intervention: Meat intake (extreme quartile)
Number of subjects: 2641

Group type: EXPERIMENTAL
Intervention: Total protein intake among those with disease history
Number of subjects: 2641
Study: 30968255

Group type: EXPERIMENTAL
Intervention: Exercise training combined with chemotherapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 10
Study: 30968301

Group type: EXPERIMENTAL
Intervention: Platelet expression of FcγRIIa in patients after MI
Number of subjects: 114

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 114

Group type: COMPARATOR
Intervention: Antiplatelet agent cangrelor
Number of subjects: 114
Study: 30968368

Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir monotherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Combination antiretroviral therapy (cART) with efavirenz/emtricitabine/tenofovir
Number of subjects: 36
Study: 30968800

Group type: EXPERIMENTAL
Intervention: Antisaccade task performance
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Flanker task performance
Number of subjects: 57
Study: 30969357

Group type: EXPERIMENTAL
Intervention: Medical Emergency Team (MET) activations
Number of subjects: 1664

Group type: EXPERIMENTAL
Intervention: Medical Emergency Team (MET) operational time
Number of subjects: 1664

Group type: EXPERIMENTAL
Intervention: Average mission time of MET
Number of subjects: 1664

Group type: EXPERIMENTAL
Intervention: Primary reason for MET activation
Number of subjects: 1664

Group type: EXPERIMENTAL
Intervention: MET deployments for emergencies at weekends
Number of subjects: 1664

Group type: EXPERIMENTAL
Intervention: Calls for cardiopulmonary resuscitation (CPR)
Number of subjects: 1664

Group type: EXPERIMENTAL
Intervention: Incidence of in-hospital cardiac arrests
Number of subjects: 1664
Study: 30969486

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention programme with whey supplements (30 g/day) and personalized resistance training regimen for 32 elderly subjects from the sarcopenic cohort.
Number of subjects: 56

Group type: COMPARATOR
Intervention: High levels of TNF-α (>11.15 pg/mL) and TWEAK (>1276.48 pg/mL) in sarcopenic patients.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Comparison of serum levels of proinflammatory cytokines and metabolic hormones between sarcopenic and non-sarcopenic subjects.
Number of subjects: 56
Study: 30971168

Group type: EXPERIMENTAL
Intervention: Symptomatic carotid plaques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contralateral side (control)
Number of subjects: 0
Study: 30971227

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 93
Study: 30971261

Group type: EXPERIMENTAL
Intervention: Asthma-related crisis events (A&E attendance or hospital admission)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EQ-5D-5 L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AQL-5D (preference-based measure derived from AQLQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TTO
Number of subjects: 0
Study: 30971304

Group type: EXPERIMENTAL
Intervention: Active TENS in addition to conscious sedation and paracervical block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo TENS in addition to conscious sedation and paracervical block
Number of subjects: 0
Study: 30971318

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study: 30971319

Group type: EXPERIMENTAL
Intervention: Maternal denial of pregnancy (case group)
Number of subjects: 140

Group type: COMPARATOR
Intervention: No maternal denial of pregnancy (control group)
Number of subjects: 140
Study: 30972619

Group type: EXPERIMENTAL
Intervention: Statin treatment (n=919)
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Control group (n=1113)
Number of subjects: 2032
Study: 30972640

Group type: EXPERIMENTAL
Intervention: Step-up fecal microbiota transplantation (single, multiple, followed by immunosuppressants)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation procedures
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Preparation of microbiota from stool using automatic system
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Delivery method of colonic transendoscopic enteral tubing
Number of subjects: 109
Study: 30972912

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a for ≥ 24 weeks
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analog (with peginterferon alfa-2a)
Number of subjects: 1669

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1669
Study: 30973338

Group type: EXPERIMENTAL
Intervention: Remote counseling by dietitians using a mobile phone app
Number of subjects: 43
Study: 30973373

Group type: EXPERIMENTAL
Intervention: Alisertib 20 mg twice daily and Pazopanib 600 mg daily (DL 2)
Number of subjects: 27
Study: 30973745

Group type: EXPERIMENTAL
Intervention: Substance Use Disorder (SUD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder (MDD)
Number of subjects: 0
Study: 30974509

Group type: EXPERIMENTAL
Intervention: HBeAg positivity
Number of subjects: 2241

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2241

Group type: EXPERIMENTAL
Intervention: Race
Number of subjects: 2241

Group type: EXPERIMENTAL
Intervention: HBV genotype
Number of subjects: 2241

Group type: EXPERIMENTAL
Intervention: Basal core promoter and precore variants
Number of subjects: 2241
Study: 30975005

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention for acute myocardial infarction
Number of subjects: 11969

Group type: EXPERIMENTAL
Intervention: Intensive care unit usage for non-STEMI patients
Number of subjects: 11969

Group type: EXPERIMENTAL
Intervention: Postdischarge costs for all patients
Number of subjects: 11969
Study: 30975126

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention in a Community-Clinical Linkage model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched non-participants (control group)
Number of subjects: 0
Study: 30975201

Group type: EXPERIMENTAL
Intervention: ATOR-1015
Number of subjects: 0
Study: 30975203

Group type: EXPERIMENTAL
Intervention: Iron status assessment using plasma ferritin and soluble transferrin receptor (sTfR) measurements.
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Higher plasma sTfR in women with severe iron depletion compared to those with iron sufficiency.
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Risk factors for modest and severe iron depletion identified through multivariable ordinal logistic regression.
Number of subjects: 985
Study: 30975567

Group type: EXPERIMENTAL
Intervention: Shingrix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Varilrix
Number of subjects: 0
Study: 30975630

Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m²), fluorouracil, and vincristine, administered in two 21-day cycles within 42 days of resection.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cisplatin, fluorouracil, and vincristine (adjuvant chemotherapy).
Number of subjects: 49
Study: 30975680

Group type: EXPERIMENTAL
Intervention: mTBI patients
Number of subjects: 19732
Study: 30975684

Group type: EXPERIMENTAL
Intervention: Patients with mTBI
Number of subjects: 19732
Study: 30975699

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen via nasal cannula
Number of subjects: 1039

Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 1039
Study: 30976125

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 10119

Group type: COMPARATOR
Intervention: Regional anaesthesia
Number of subjects: 10119

Group type: EXPERIMENTAL
Intervention: Intubation with rocuronium
Number of subjects: 10119

Group type: COMPARATOR
Intervention: Intubation with suxamethonium
Number of subjects: 10119
Study: 30976202

Group type: EXPERIMENTAL
Intervention: High ZEB1 protein expression
Number of subjects: 75
Study: 30976292

Group type: EXPERIMENTAL
Intervention: Intra-abdominal view (IAV) score based on observed factors
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Intra-abdominal view (IAV) factors
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: IAV score
Number of subjects: 283
Study: 30976651

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High molecular weight von Willebrand factor (HMW-vWF) multimers
Number of subjects: 21
Study: 30976780

Group type: EXPERIMENTAL
Intervention: Inflammation defined as CRP >5 mg/L or AGP >1 g/L, or both
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Longitudinal models adjusting for inflammation
Number of subjects: 451

Group type: COMPARATOR
Intervention: CS models
Number of subjects: 451
Study: 30976898

Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy using esophageal Doppler monitoring (EDM) during laparoscopic adrenalectomy for PCC patients.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (HIAT patients) receiving standard care without EDM monitoring.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PCC patients receiving goal-directed fluid therapy using EDM.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PCC patients post-tumor resection.
Number of subjects: 15
Study: 30977682

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30977792

Group type: EXPERIMENTAL
Intervention: Postoperative atrial fibrillation (POAF)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Postoperative C-reactive protein (CRP)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Left atrial volume index
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Aortic clamp time
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Long-term atrial fibrillation (LTAF)
Number of subjects: 96
Study: 30977945

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P)
Number of subjects: 2522